Targeted therapy of chronic myeloid leukemia
- 1 September 2010
- journal article
- review article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 80 (5), 584-591
- https://doi.org/10.1016/j.bcp.2010.05.001
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemiaNature Genetics, 2009
- Activation of tyrosine kinases by mutation of the gatekeeper threonineNature Structural & Molecular Biology, 2008
- Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemiaLeukemia & Lymphoma, 2008
- Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemiaGenes & Development, 2007
- The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of ageBest Practice & Research Clinical Haematology, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- Surface comparison of active and inactive protein kinases identifies a conserved activation mechanismProceedings of the National Academy of Sciences, 2006
- Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in miceProceedings of the National Academy of Sciences of the United States of America, 2006
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000